BridgeBio Pharma, Inc.
infigratinib
hypochondroplasia
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for infigratinib in hypochondroplasia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Depleter for ATTR-CM Development candidate nomination Submit IND to the FDA in 2027”